Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling
about
In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazoleAdvances in the treatment of invasive neonatal candidiasisAnidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination.Pharmacokinetics of caspofungin acetate to guide optimal dosing in cats.Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patientsAntifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Human tissue distribution of voriconazole.In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model.Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model.Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasisThe echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy.Antifungal pharmacokinetics and pharmacodynamicsAnidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.Anidulafungin: review of a new echinocandin antifungal agent.Pharmacological assessment of the medicinal potential of Acacia mearnsii De Wild.: antimicrobial and toxicity activities.In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.Echinocandin antifungals: review and update.Emerging echinocandins for treatment of invasive fungal infections.The safety of anidulafungin.The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.Anidulafungin: a new echinocandin for candidal infections.The echinocandins.Anidulafungin in the treatment of invasive fungal infections.CNS pharmacokinetics of antifungal agents.Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective.Candida endophthalmitis: focus on current and future antifungal treatment options.Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysisPharmacology and antifungal properties of anidulafungin, a new echinocandin.Cerebral aspergillosis: tissue penetration is the key.Tissue penetration of antifungal agents.Echinocandin pharmacodynamics: review and clinical implications.Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis.Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Approach to the Solid Organ Transplant Patient with Suspected Fungal Infection.
P2860
Q24538858-3841BA3E-6815-474D-988E-43901D2E96C1Q27022585-FF8A6F88-E5B9-43AF-ADC7-CB085EADFD94Q33490772-79F48D99-CA1F-412C-A6FD-44E79F968253Q33757912-5CE59158-6E35-4088-AEE1-1102106AAA47Q33983506-23F67770-32E5-4306-8D77-B0CC98883D99Q34045450-2EC94181-C633-4F61-9AB3-C70DD654F863Q34104748-5074BE25-2C4E-4FAD-A063-FBF7625C98EAQ34352100-E3C6505A-28DA-4CE2-8235-5318C813FA68Q34505582-44B070B8-F56F-4E47-8F34-C8EA381F8921Q34529318-1938E95B-CA90-47A5-9FA4-D6833D5C33CEQ34881309-5BEEB6E8-575C-41AD-A831-B3E206032064Q35105763-83BF96C4-3C88-45EA-933C-EC40AAEF4C36Q35127833-E1EDBFAA-E7AA-478E-841A-05F3D59D584DQ35185757-E1B9C88E-B965-4344-84AE-7E8EA283A398Q35663841-5A40C353-F61B-45EF-AD8B-98053DB3A8F7Q35689202-788EF553-A0C6-45FF-BB74-1B4AA32CA4E9Q35745822-B30FBD1D-6AFA-4FF7-A264-E068D4A9DD76Q35917456-D1B8A17A-299B-4FCB-9F2E-7D0746898723Q35933900-F493067D-1F76-47A4-98DF-48763A985950Q36425025-B69BFCA2-0E5D-4DA1-9FFA-0D15F7CEE92FQ36441524-D7B7C3F0-D2C1-47EF-899B-27FFAE4DE260Q36458402-14D0A6E7-E7E4-4378-A16A-AAB02C05D7DCQ36624970-875701C4-DF85-44F5-8FC1-8F0B4A5328BCQ36626518-49D16A11-54BE-4D2E-AEEC-D473DA14E80FQ36723788-2A96E7E4-6511-412E-A5B3-1B7E0C347800Q36742397-B712655C-B3F8-4FDB-A4E9-6DF18513C23EQ36822941-1407C51B-FF78-41CC-A7C1-E95222B17ABBQ36909333-F6F0471F-2905-4C91-A37B-723F16A59707Q36948094-8FE6E5DF-A937-4865-9E12-0C63A5DF1DC2Q37015976-EBFB74A9-7964-4AD4-9425-847F1DEEA807Q37204192-B3C9097F-71D2-4BA5-8AFA-970CD4ADFA23Q37359613-0FD020A0-F902-43D5-A3AA-DA2DAA30B521Q37405288-509DEF11-5120-4590-A0D9-FE27261470B9Q37544911-B27C820C-6BC8-4FC9-8FE7-AAFCD356AF35Q37718385-6FD3B7D5-8C49-4800-A098-043B6CDAFA36Q37720794-7EC6D943-D0DD-48E2-8198-B1A22C90A780Q37785979-BDBAF7CA-534A-45BB-86EE-60B7354365A4Q37829260-4AC2F347-A5CB-4780-8318-4C75E9EDE71CQ38681635-E42C75F9-AFC6-4FEB-B225-6DE7F7928654Q38688900-D4DCE489-0D42-4849-AD43-29C7843AE880
P2860
Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pharmacokinetic and pharmacody ...... using optimal plasma sampling
@ast
Pharmacokinetic and pharmacody ...... using optimal plasma sampling
@en
type
label
Pharmacokinetic and pharmacody ...... using optimal plasma sampling
@ast
Pharmacokinetic and pharmacody ...... using optimal plasma sampling
@en
prefLabel
Pharmacokinetic and pharmacody ...... using optimal plasma sampling
@ast
Pharmacokinetic and pharmacody ...... using optimal plasma sampling
@en
P2093
P2860
P1476
Pharmacokinetic and pharmacody ...... using optimal plasma sampling
@en
P2093
D Mickiene
J S Bacher
R Petraitiene
S C Piscitelli
V Petraitis
P2860
P304
P356
10.1128/AAC.45.10.2845-2855.2001
P407
P577
2001-10-01T00:00:00Z